Nuplazid
NDC Package 63090-170-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Nuplazid is pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. Marketed by Acadia Pharmaceuticals Inc, this product is identified by NDC 63090-170 and is authorized under FDA application NDA207318.

Identification & Billing

NDC Package Code
63090-170-60
Package Description
60 TABLET, COATED in 1 BOTTLE, PLASTIC
Product Code
63090-170
11-Digit Billing Format
63090017060
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
60 EA

Clinical Specifications

Proprietary Name
Nuplazid
Dosage Form
-
Usage Information
Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions). Pimavanserin belongs to a class of drugs known as atypical antipsychotics, though it works differently from most other drugs in this class.

Regulatory & Marketing

Labeler Name
Acadia Pharmaceuticals Inc
FDA Application #
NDA207318
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-29-2016
End Marketing Date
06-21-2022
Listing Expiration
06-21-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63090-170-60 identifies a specific commercial package of 60 tablet, coated in 1 bottle, plastic of Nuplazid, labeled by Acadia Pharmaceuticals Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Acadia Pharmaceuticals Inc on April 29, 2016. The current certification is valid through June 21, 2022.

What are the primary indications for this medication?

Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions). Pimavanserin belongs to a class of drugs known as atypical antipsychotics, though it works differently from most other drugs in this class.

How is this Acadia Pharmaceuticals Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63090017060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63090-170-60
11-Digit CMS (5-4-2)
63090-0170-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.